Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100654 | 0.88 | FLT1 (0.49) | FLT1FLT4KDRGPR27RAB9A | |
| SCHEMBL16142876 | 0.86 | NPC1 (0.45) | RAB9ANPC1MEN1KMT2AMAOA | |
| SCHEMBL4926140 | 0.82 | SMN1; SMN2 (0.51) | FLT1FLT4KDRRAB9ANPC1 | |
| SCHEMBL27007635 | 0.82 | NPC1 (0.62) | FLT1FLT4KDRGPR27RAB9A | |
| SCHEMBL506513 | 0.81 | DGAT1 (0.54) | FLT1FLT4KDRGPR27RAB9A | |
| SCHEMBL31189207 | 0.81 | NPC1 (0.44) | RAB9ANPC1MEN1KMT2AMAOA | |
| SCHEMBL22745717 | 0.81 | NPC1 (0.44) | RAB9ANPC1MEN1KMT2AMAOA | |
| SCHEMBL16823601 | 0.81 | POLB (0.57) | FLT1FLT4KDRRAB9ANPC1 | |
| SCHEMBL1697081 | 0.80 | FLT1 (0.54) | FLT1FLT4KDRGPR27RAB9A | |
| SCHEMBL23604904 | 0.79 | GAA (0.56) | RAB9ANPC1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722741-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1784388-B3 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-20100160285-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-7737135-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-1784388-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | EP | disclosed |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| EP-1784388-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021759-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | FLT1 2023/4885FLT4 3315/4885KDR 3228/4885 |
| US-20100160285-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | FLT1 2023/4885FLT4 3315/4885KDR 3228/4885 |
| US-20080132480-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | FLT1 2023/4885FLT4 3315/4885KDR 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.